Cargando…

Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and ALK Genotyping via Cell-Free Circulating Tumor DNA Profiling

SIMPLE SUMMARY: Neuroblastoma is composed of several molecular subtypes that are associated with distinct outcomes. Risk classification into these subtypes is routinely assessed at diagnosis and is based on the evaluation of well-defined chromosomal changes found in the tumor DNA which requires a ti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kahana-Edwin, Smadar, Cain, Lucy E., McCowage, Geoffrey, Darmanian, Artur, Wright, Dale, Mullins, Anna, Saletta, Federica, Karpelowsky, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267662/ https://www.ncbi.nlm.nih.gov/pubmed/34282791 http://dx.doi.org/10.3390/cancers13133365

Ejemplares similares

From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients
por: Grebstad Tune, Benedicte, et al.
Publicado: (2023)

Molecular profiling of childhood cancer: Biomarkers and novel therapies
por: Saletta, Federica, et al.
Publicado: (2014)

NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB
por: Moukhaiber, Perla, et al.
Publicado: (2020)

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2017)

Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
por: Kumps, Candy, et al.
Publicado: (2013)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
por: Berko, Esther R., et al.
Publicado: (2023)

Platform Comparison for Evaluation of ALK Protein Immunohistochemical Expression, Genomic Copy Number and Hotspot Mutation Status in Neuroblastomas
por: Yan, Benedict, et al.
Publicado: (2014)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

Psychosocial Assessment Using Telehealth in Adolescents and Young Adults With Cancer: A Partially Randomized Patient Preference Pilot Study
por: Chalmers, John Alexander, et al.
Publicado: (2018)

Ub-ISAP: a streamlined UNIX pipeline for mining unique viral vector integration sites from next generation sequencing data
por: Kamboj, Atul, et al.
Publicado: (2017)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

Multiple MAPK Cascades Regulate the Transcription of IME1, the Master Transcriptional Activator of Meiosis in Saccharomyces cerevisiae
por: Kahana-Edwin, Smadar, et al.
Publicado: (2013)

From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma
por: Decaesteker, Bieke, et al.
Publicado: (2021)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

5′ ALK Amplification in Neuroblastoma: A Case Report
por: Akhavanfard, Sara, et al.
Publicado: (2021)

Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
por: Aktaş, Tekincan Çağrı, et al.
Publicado: (2023)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy
por: Kamili, Alvin, et al.
Publicado: (2020)

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
por: Dietz, Steffen, et al.
Publicado: (2020)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
por: Guan, J., et al.
Publicado: (2016)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Activating mutations in ALK provide a therapeutic target in neuroblastoma
por: George, Rani E., et al.
Publicado: (2008)

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
por: Claeys, Shana, et al.
Publicado: (2017)

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
por: Tucker, Elizabeth R., et al.
Publicado: (2023)

WANTED: Better neuroblastoma biomarkers and better stratification
por: London, Wendy B.
Publicado: (2022)

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC
por: Zito Marino, Federica, et al.
Publicado: (2020)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT
por: Debruyne, D N, et al.
Publicado: (2016)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

Detection of tumor ALK status in neuroblastoma patients using peripheral blood
por: Combaret, Valérie, et al.
Publicado: (2015)

ALK and GSK3: Shared Features of Neuroblastoma and Neural Crest Cells
por: Gonzalez Malagon, Sandra G, et al.
Publicado: (2018)

ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
por: Lee, Ji Won, et al.
Publicado: (2018)

Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration
por: Huang, Hao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0vh9betnb6ricigfhc8460fa6c